Qiagen posts investor presentation outlining Q2 2026 results and growth strategy
Reuters2026/08/07 10:06- Qiagen outlined 2028 targets of about 7% net sales CAGR at constant exchange rates, adjusted operating margin of at least 31%.
- Strategy calls for at least USD 2 billion net sales at constant exchange rates from growth pillars by 2028.
- Plan includes at least 250 bps adjusted operating margin expansion from 2024 to 2028, supported by efficiency and digitization.
- Capital allocation framework targets at least USD 1 billion in shareholder returns from 2024 to 2028, excluding M&A.
- 2028 product targets include QIAcuity net sales of at least USD 250 million, QIAstat-Dx at least USD 200 million, both at constant exchange rates.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
Fogo Foundation Attacked, Approximately 400 Million FOGO Tokens Transferred
Blue Owl (OWL.US) teams up with PIMCO to tailor a $2.4 billion GPU financing for IREN (IREN.US)
A $2.4 billions debt financing round, led by funds under Blue Owl Capital Inc., has been finalized. The funds will be allocated to cloud service provider IREN Ltd. to purchase NVIDIA's Blackwell Ultra GPUs, supporting the development of its data center campus in Canada.
Crypto prices
More
